The effect of anticholinergic agents on gastro-oesophageal reflux and related disorders

Expert Opinion on Drug Safety

Volumn 7, Issue 2, 2008, Pages 173-180

  van Soest, Eva M ^a   Dieleman, Jeanne P ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anticholinergic agents; Atropine; Gastro oesophageal reflux disease; Oesophageal adenocarcinoma; Tricyclic antidepressants

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; DICYCLOVERINE; PIRENZEPINE; SPASMOLYTIC AGENT;

CARDIA CARCINOMA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABLE COLON; LOWER ESOPHAGUS SPHINCTER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOOTH MUSCLE RELAXATION; STOMACH ACID SECRETION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CHOLINERGIC ANTAGONISTS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; RISK FACTORS;

EID: 41349120265     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.2.173     Document Type: Review

References (58)

1. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-85
2. Lagergren J, Bergstrom R, Lindgren A, Nyren O, Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31
3. Solaymani-Dodaran M, Logan RFA, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070-4
4. Wu AH, Tseng C, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003;98:940-8
5. Blot WJ, Devesa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma: an update, JAMA 1993;270:1320
6. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9
7. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91
8. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United Stares. Cancer 1998;83:2049-53
9. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3
10. van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005;54:1062-6
11. Wang HH, Hsieh C, Antonioli DA. Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esophageal sphincter (United States). Cancer Causes Control 1994;5:573-8
12. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005;40:275-85
13. Dent J. Microscopic esphageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007;5:4-16
14. Quigley EMM, Hungin APS. Review article: quality-of-life issues in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;22(Suppl 1):41-7
15. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002;97:225-9
16. Johansson J, Hakansson HO, Mellblom L, et al. Risk factors for Barrett's oesophagus: a population-based approach. Scan J Gastroenterol 2007;42:148-56
17. Loffeld RJLF. Gastro-oesophageal reflux disease - experience in daily practice: symtpoms and symptom assessment. Scan J Gastroenterol 2006;41(Suppl 243):3-6
18. Flejou J-F. Barrett's esophagus: from metaplasia to dysplasia and cancer. Gut 2005;54(Suppl 1):i6-12
19. Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med 1997;336:924-32
20. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109:601-10
21. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980;65:256-67
22. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 1988;29:1020-8
23. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982;307:1547-52
24. Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988;95:593-9
25. Schoeman MN, Tippett MD, Akkermans LMA, et al. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995;108:83-91
26. Bettarello A, Tuttle SG, Grossman MI. Effect of autonomic drugs on gastroesophageal reflux. Gastroenterology 1960;39:340-6
27. Fisher RS, Malmud LS, Roberts GS, Lobis IF. The lower esophageal sphincter as a barrier to gastroesophageal reflux. Gastroenterology 1977;72:19-22
28. Lind JF, Crispin JS, McIver DK. The effect of atropine on the gastroesophageal sphincter. Can J Physiol Pharmacol 1968;46:233-8
29. Skinner DB, Camp TFJ. Relation of esophageal reflux to lower esophageal sphincter pressures decreased by atropine. Gastroenterology 1968;54:543-51
30. Brock-Utne J. Domperidone antagonizes the relaxant effect of atropine on the lower esophageal sphincter. Anesth Analg 1980;59:921-4
31. Brock-Utne JG, Rubin J, McAravey R, et al. The effect of hyoscine and atropine on the lower oesophageal sphincter. Anaesth Intensive Care 1977;5:223-5
32. Dow TG, Brock-Utne JG, Rubin J, et al. The effect of atropine on the lower esophageal sphincter in late pregnance. Obstet Gynecol 1978;51:426-30
33. Laitinen S, Mokka RE, Valanne JV, Larmi TK. Anaesthesia induction and lower oesophageal sphincter pressure. Acta Anaesthesiol Scand 1978;22:16-20
34. Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 1995;109:1547-54
35. Lidums I, Checklin H, Mittal RK, Holloway RH. Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 1998;43:12-6
36. Fang JC, Sarosiek I, Yamamoto Y, et al. Cholinergic blockade inhibits gastro-oesophageal reflux and transient lower oesophageal sphincter relaxation through a central mechanism. Gut 1999;44:603-7
37. Aggestrup S, Jensen SL. Effects of pirenzepine and atropine on basal lower esophageal pressure and gastric acid secretion in man: a placebo-controlled randomized study. Dig Dis 1991;9:360-4
38. Koerselman J, Pursnani KG, Peghini P, et al. Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study. Am J Gastroenterol 1999;94:925-30
39. Ciccaglione AF, Grossi L, Cappello G, et al. Effect of hyoscine N-butylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96:2306-11
40. Goyal RK. Muscarinic receptor subtypes: Physiology and clinical implications. N Engl J Med 1989;321:1022-9
41. Uchiyama T, Chess-Williams R. Muscarinic receptor subtypes of the bladder and gastrointestinal tract. J Smooth Muscle Res 2004;40:237-47
42. Blackwell JN, Dalton CB, Castell DO. Oran pirenzepine does not affect esophageal pressures in men. Dig Dis Sci 1986;31:230-5
43. Niemela S, Jaaskelainen T, Lehtola J, et al. Pirenzepine in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study. Scand J Gastroenterol 1986;21:1193-9
44. Helm JF, Dodds WJ, Pelc LR, et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med 1984;310:284-8
45. Rashid MU, Bateman DN. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. Br J Clin Pharmacol 1990;30:25-34
46. Phaosawasdi K, Malmud LS, Tolin RD, et al. Cholinergic effect on esophageal transit and clearance. Gastroenterology 1981;81:915-20
47. Salas M, Hofman A, Stricker BHC. Confounding by indication: an example of variation in the use of epidemiologic therminology. Am J Epidemiol 1999;149:981-3
48. Harding SM. Recent clinical investigations examining the association of asthma and gastroesophageal reflux. Am J Med 2003;115:39S-44S
49. Crowell MD, Zayat EN, Lacy BE, et al. The effect of an inhaled B2-adrenergic agonist on lower esophageal function. A dose-response study. Chest 2001;120:1184-9
50. Corley DA, Levin TR, Habel LA, Buffler PA. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006;101:1-8
51. Morice AH. Epidemiology of cough. Pulm Pharmacol Ther 2002;15:253-9
52. Mohamed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther 2005;21:821-7
53. van Soest EM, Dieleman JP, Siersema PD, et al. Tricyclic antidepressants and the risk of reflux esophagitis. Am J Gastroenterol 2007;102:1-8
54. Zimmerman J. Irritable bowel, smoking and oesophageal acid exposure: an insight into the nature of symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2004;20:1297-303
55. Chow W, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7
56. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinoma in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998;7:749-56
57. Lagergren J, Bergstrom R, Adami H, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165-75
58. Ranka S, Gee JM, Johnson IT, et al. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. Digestion 2006;74:109-15